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BACKGROUND
Whether the direct factor Xa inhibitor rivaroxaban can prevent thromboembolic 
events after transcatheter aortic-valve replacement (TAVR) is unclear.
METHODS
We randomly assigned 1644 patients without an established indication for oral an-
ticoagulation after successful TAVR to receive rivaroxaban at a dose of 10 mg daily 
(with aspirin at a dose of 75 to 100 mg daily for the first 3 months) (rivaroxaban 
group) or aspirin at a dose of 75 to 100 mg daily (with clopidogrel at a dose of 75 mg 
daily for the first 3 months) (antiplatelet group). The primary efficacy outcome was 
the composite of death or thromboembolic events. The primary safety outcome was 
major, disabling, or life-threatening bleeding. The trial was terminated prematurely 
by the data and safety monitoring board because of safety concerns.
RESULTS
After a median of 17 months, death or a first thromboembolic event (intention-to-treat 
analysis) had occurred in 105 patients in the rivaroxaban group and in 78 patients in 
the antiplatelet group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; 
hazard ratio with rivaroxaban, 1.35; 95% confidence interval [CI], 1.01 to 1.81; 
P = 0.04). Major, disabling, or life-threatening bleeding (intention-to-treat analysis) 
had occurred in 46 and 31 patients, respectively (4.3 and 2.8 per 100 person-years; 
hazard ratio, 1.50; 95% CI, 0.95 to 2.37; P = 0.08). A total of 64 deaths occurred in the 
rivaroxaban group and 38 in the antiplatelet group (5.8 and 3.4 per 100 person-
years, respectively; hazard ratio, 1.69; 95% CI, 1.13 to 2.53).
CONCLUSIONS
In patients without an established indication for oral anticoagulation after suc-
cessful TAVR, a treatment strategy including rivaroxaban at a dose of 10 mg daily 
was associated with a higher risk of death or thromboembolic complications and 
a higher risk of bleeding than an antiplatelet-based strategy. (Funded by Bayer and 
Janssen Pharmaceuticals; GALILEO ClinicalTrials.gov number, NCT02556203.)
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Transcatheter aortic-valve replace-ment (TAVR) is indicated in symptomatic severe aortic stenosis.1-7 Thromboembolic 
complications (stroke, systemic embolism, valve 
thrombosis, and venous thromboembolism) have 
been observed after TAVR. Observational data sug-
gest that subclinical leaflet thrombosis may occur 
with bioprosthetic valves and that this phenom-
enon may be associated with an increased risk of 
cerebrovascular events and prevented or reversed 
by anticoagulation.8-13 Current practice guidelines 
recommend the use of dual antiplatelet therapy 
early after TAVR,14,15 although the recommenda-
tion is based mainly on expert consensus.
Rivaroxaban directly inhibits factor Xa and has 
been shown to reduce the risk of thromboembo-
lism in different clinical settings.16-18 The 10-mg 
daily dose has been approved for the prevention 
of venous thromboembolism in several countries. 
However, there is a dearth of evidence for routine 
use of anticoagulation after TAVR for the pre-
vention of thromboembolic events. In addition, 
patients undergoing TAVR are typically elderly, 
frail, and at increased risk for both ischemic and 
bleeding complications. In GALILEO (Global Study 
Comparing a Rivaroxaban-based Antithrombotic 
Strategy to an Antiplatelet-based Strategy after 
Transcatheter Aortic Valve Replacement to Opti-
mize Clinical Outcomes), we investigated the role 
of a treatment strategy including anticoagulation 
with rivaroxaban at a dose of 10 mg daily as com-
pared with an antiplatelet strategy in patients 
without established indications for anticoagula-
tion after successful TAVR.
Me thods
Trial Design and Oversight
GALILEO was a randomized, open-label, event-
driven, multicenter trial.19 The trial was conducted 
in compliance with the International Conference 
on Harmonisation and the Declaration of Hel-
sinki. The protocol (available with the full text of 
this article at NEJM.org) was approved by the 
ethics committees and corresponding health au-
thorities for all participating sites. All the patients 
provided written informed consent to participate.
The trial was supported by the sponsors, Bayer 
and Janssen Pharmaceuticals. The sponsors and 
the academic investigators designed and super-
vised the trial, which was executed with the as-
sistance of the two clinical research organizations, 
Cardialysis (Rotterdam, the Netherlands) and the 
Center for Interventional Cardiovascular Research 
and Clinical Trials (Mount Sinai Hospital, New 
York). The executive committee included mem-
bers of the academic leadership and the sponsors. 
Data analyses were conducted by DATAN (Havix-
beck, Germany). An independent data and safety 
monitoring board provided oversight by periodi-
cally reviewing all reported serious adverse events. 
The first, second, and last authors wrote the first 
draft of the manuscript and made the decision to 
submit it for publication. All the authors reviewed 
and critiqued subsequent drafts and vouch for the 
accuracy and completeness of the data and for 
the fidelity of the trial to the protocol. (Addi-
tional information about trial organization is 
provided in the Supplementary Appendix, avail-
able at NEJM.org.)
Patient Selection and Randomization
Men and women 18 years of age or older were 
eligible for participation in the trial if they had 
undergone successful TAVR for treatment of aor-
tic-valve stenosis. Successful TAVR was defined as 
correct positioning of any single approved trans-
catheter bioprosthetic aortic valve into the prop-
er anatomical location with the intended valve 
performance and without periprocedural compli-
cations.20 Key exclusion criteria were any estab-
lished indication for long-term anticoagulation 
and any absolute indication for dual antiplatelet 
therapy. (See Supplementary Appendix text and 
Table S1 for screening procedures and a com-
plete list of the inclusion and exclusion criteria.) 
After written informed consent had been obtained, 
eligible patients were randomly assigned (in a 1:1 
ratio) through an interactive Web-response sys-
tem to either the rivaroxaban group or the anti-
platelet group 1 to 7 days after TAVR and before 
hospital discharge.
Trial Treatment and Follow-up
The anticoagulant (experimental) group was as-
signed to receive rivaroxaban at a dose of 10 mg 
daily plus aspirin at a dose of 75 to 100 mg daily 
for 3 months, followed by rivaroxaban monothera-
py (10 mg daily). The antiplatelet (control) group 
was assigned to receive aspirin at a dose of 75 to 
100 mg daily plus clopidogrel at a dose of 75 mg 
daily for 3 months (patients who had not previ-
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ously received clopidogrel were recommended to 
receive a single loading dose of ≥300 mg), fol-
lowed by aspirin monotherapy (75 to 100 mg 
daily).
Patients in the rivaroxaban group in whom 
atrial fibrillation developed were to receive riva-
roxaban at a dose of 20 mg once daily (or 15 mg 
for those with an estimated glomerular filtra-
tion rate of 30 to 50 ml per minute per 1.73 m2 
of body-surface area). In the antiplatelet group, 
patients in whom new-onset atrial fibrillation 
developed were to receive vitamin K antagonists 
(targeting an international normalized ratio of 2 
to 3) to replace clopidogrel within 3 months after 
randomization or to replace aspirin thereafter.
Rivaroxaban was centrally supplied to the 
sites as trial medication. Clopidogrel, aspirin, 
and vitamin K antagonists were supplied accord-
ing to local practice. Patients were followed at 1, 
3, and 6 months and every 6 months thereafter. 
(Details of the follow-up procedures and recom-
mendations for concomitant medications are pro-
vided in the Supplementary Appendix.)
Outcome Measures
The primary efficacy outcome was the composite 
of death from any cause or thromboembolic 
events, including any stroke, myocardial infarction, 
symptomatic valve thrombosis, systemic embo-
lism (not involving the central nervous system), 
deep-vein thrombosis, or pulmonary embolism. 
The primary safety outcome was the composite 
of life-threatening, disabling, or major bleeding. 
The secondary efficacy outcome was defined as 
the primary efficacy outcome with death from 
cardiovascular causes replacing death from any 
cause. The net-benefit outcome included all com-
ponents of the primary efficacy and primary 
safety outcomes. All the above outcomes and their 
components were adjudicated in a blinded man-
ner by an independent clinical-events committee 
according to Valve Academic Research Consor-
tium definitions.20 (See Table S2 for detailed defi-
nitions.)
Statistical Analysis
The primary hypothesis was that the rivaroxaban 
group would be superior to the antiplatelet group 
with respect to the time from randomized treat-
ment assignment to the first occurrence of any 
component of the primary efficacy outcome. The 
trial was event-driven; we estimated that 440 pri-
mary efficacy outcome events would provide the 
trial with 80% power to detect a 20% lower rela-
tive risk in the rivaroxaban group than in the 
antiplatelet group. (Details on the power calcu-
lation and statistical methods are provided in 
the Supplementary Appendix.)
No formal interim analyses for efficacy or futil-
ity were planned. After review by the data and 
safety monitoring board on August 7, 2018, im-
mediate termination of the trial was recommended 
because of safety concerns. The trial leadership 
and the sponsors accepted this recommendation 
for trial termination on August 13, 2018 (efficacy 
cutoff date). Because the trial was terminated 
early, only 183 patients reached the primary ef-
ficacy outcome (42% of the planned 440).
The statistical analysis plan originally speci-
fied that the primary efficacy outcome was to be 
analyzed for noninferiority (with a noninferiori-
ty margin for the upper boundary of the hazard 
ratio of 1.20) in the on-treatment data set; a hi-
erarchical testing strategy specified that no tests 
for superiority would be performed if noninferi-
ority was not shown. However, it was subse-
quently decided to present conventional two-
sided P values to test for the between-group 
difference for both the primary efficacy outcome 
and the primary safety outcome; the approach 
described below and in the Results section is 
based on that decision.
The main analyses were performed according 
to the intention-to-treat principle. For time-to-
event analyses, hazard ratios and 95% confidence 
intervals were generated with Cox proportional-
hazards models. The confidence intervals were 
not adjusted for multiple comparisons, and there-
fore inferences drawn from these intervals may 
not be reproducible. Kaplan–Meier curves were 
used to show the incidence of outcomes over time. 
The proportionality assumption for the primary 
efficacy and safety outcomes was not violated.
For the primary efficacy outcome and the 
primary safety outcome, conventional two-sided 
log-rank P values were calculated. Prespecified 
subgroup analyses followed Cox proportional-
hazards methods. To describe early and late risks 
of outcome events, we performed landmark analy-
ses on a post hoc basis with the landmark time 
point set at 90 days after randomization.
For the on-treatment analyses, trial out-
comes were included if they occurred before 
premature permanent discontinuation of the 
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assigned trial regimen. The time of premature 
permanent discontinuation was defined as 2 days 
after the last ingestion of a trial medication. 
On-treatment Cox regression analyses were per-
formed by imposing additional censoring at the 
day of premature permanent discontinuation of 
the trial regimen.
R esult s
Trial Population
From December 2015 through May 2018, a total 
of 1644 patients underwent randomization after 
successful TAVR in 136 centers in 16 countries 
(Table S3); 826 patients were randomly assigned 
to the rivaroxaban group and 818 to the antiplate-
let group. The median time from TAVR to ran-
domization was 2.0 days (range, 0 to 8). Baseline 
characteristics are shown in Table 1. The mean 
(±SD) age was 80.6±6.6 years; 49.5% of the pa-
tients were female.
Adherence and Follow-up
Follow-up was complete for 96.8% of the pa-
tients, and vital status was available for 98.0% 
(Fig. 1); the median trial duration was 17 months 
(interquartile range, 13 to 21). Throughout the 
trial period, 307 patients in the rivaroxaban group 
prematurely discontinued the trial regimen, as 
compared with 194 in the antiplatelet group 
(Tables S4 and S5 and Fig. S1). In the rivaroxa-
ban group, the median exposure to rivaroxaban 
was 428 days (interquartile range, 171 to 581), 
and the median exposure to aspirin was 90 days 
(interquartile range, 84 to 94). In the antiplatelet 
group, the median exposure to aspirin was 474 
days (interquartile range, 298 to 603), and the 
median exposure to clopidogrel was 90 days 
(interquartile range, 85 to 93). New-onset atrial 
fibrillation developed in 11.0% of the trial popu-
lation (Table S6).
Primary and Secondary Efficacy Outcomes
In the intention-to-treat analysis, death or first 
thromboembolic event (the primary efficacy out-
come) occurred in 105 patients in the rivaroxaban 
group and in 78 patients in the antiplatelet group 
(incidence rates, 9.8 and 7.2 per 100 person-years, 
respectively; hazard ratio with rivaroxaban, 1.35; 
95% confidence interval [CI], 1.01 to 1.81; P = 0.04) 
(Fig. 2A and Table 2). This effect was consistent 
across prespecified subgroups (Fig. S2).
Death from cardiovascular causes or any 
thromboembolic event (the key secondary out-
come) occurred in 83 patients in the rivaroxaban 
group and in 68 patients in the antiplatelet group 
(incidence rates, 7.8 and 6.3 per 100 person-years, 
respectively; hazard ratio, 1.22; 95% CI, 0.89 to 
1.69). Symptomatic valve thrombosis occurred in 
3 patients in the rivaroxaban group and in 7 pa-
tients in the antiplatelet group (incidence rates, 
0.3 and 0.6 per 100 person-years, respectively; 
hazard ratio, 0.43; 95% CI, 0.11 to 1.66). Rates 
of stroke and myocardial infarction did not dif-
fer significantly between the two groups.
A total of 64 deaths occurred in the rivaroxaban 
group, and 38 occurred in the antiplatelet group 
(incidence rates, 5.8 and 3.4 per 100 person-
years, respectively; hazard ratio for rivaroxaban, 
1.69; 95% CI, 1.13 to 2.53) (Fig. 2B and Table 2). 
Noncardiovascular mortality rates were 2.6 and 
1.0 per 100 person-years, respectively (hazard 
ratio, 2.67; 95% CI, 1.33 to 5.35). Cardiovascular 
mortality rates were 3.2 and 2.4 per 100 person-
years, respectively (hazard ratio, 1.30; 95% CI, 
0.79 to 2.14). Adjudicated causes of death are 
presented in Tables S7 through S9.
Primary Safety Outcome
In the intention-to-treat analysis, life-threaten-
ing, disabling, or major bleeding (the primary 
safety outcome) occurred in 46 patients in the 
rivaroxaban group and 31 patients in the anti-
platelet group (incidence rates, 4.3 and 2.8 per 
100 person-years, respectively; hazard ratio with 
rivaroxaban, 1.50; 95% CI, 0.95 to 2.37; P = 0.08) 
(Fig. 2C). There was no significant between-
group difference in the rate of life-threatening 
or disabling bleeding (1.6 and 1.5 per 100 person-
years, respectively; hazard ratio, 1.06; 95% CI, 
0.55 to 2.06). Bleeding rates according to other 
prespecified definitions occurred more frequently 
in the rivaroxaban group than in the antiplatelet 
group (Table 2). Subgroup analyses for the pri-
mary safety outcome are shown in Figure S3.
Landmark and On-Treatment Analyses
Landmark analyses for the primary efficacy and 
safety outcomes and for death from any cause 
are shown in Figures S4 through S6. In the on-
treatment analyses, a primary efficacy outcome 
event occurred in 68 patients during use of riva-
roxaban and in 63 patients during use of anti-
platelet therapy (incidence rates, 8.1 and 6.6 per 
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100 person-years, respectively; hazard ratio with 
rivaroxaban, 1.21; 95% CI, 0.86 to 1.70). A pri-
mary safety outcome event occurred in 39 and 
28 patients, respectively (incidence rates, 4.6 and 
2.9 per 100 person-years; hazard ratio, 1.53; 95% 
CI, 0.94 to 2.49; P = 0.08). There were 26 and 24 
deaths during treatment, respectively (incidence 
rates, 3.0 and 2.5 per 100 person-years; hazard 
Characteristic
Rivaroxaban Group 
(N = 826)
Antiplatelet Group 
(N = 818)
Demographic and clinical characteristics
Age — yr 80.4±7.1 80.8±6.0
Male sex — no. (%) 426 (51.6) 405 (49.5)
Body-mass index† 28.1±5.5 28.2±5.7
Hypertension — no. (%) 720 (87.2) 697 (85.2)
Diabetes mellitus — no. (%) 236 (28.6) 235 (28.7)
EuroSCORE II‡ 4.1±3.9 4.1±3.7
EuroSCORE II risk category — no. (%)‡
High 50 (6.1) 64 (7.8)
Intermediate 139 (16.8) 140 (17.1)
Low 636 (77.0) 613 (74.9)
Missing 1 (0.1) 1 (0.1)
STS risk score§ 4.0±3.2 4.3±3.5
STS risk category — no. (%)§
High 65 (7.9) 74 (9.0)
Intermediate 383 (46.4) 388 (47.4)
Low 378 (45.8) 356 (43.5)
Congestive heart failure — no. (%) 394 (47.7) 380 (46.5)
NYHA class III or IV — no. (%) 250 (30.3) 222 (27.1)
Coronary artery disease — no. (%)¶ 325 (39.3) 305 (37.3)
Previous stroke — no. (%) 51 (6.2) 35 (4.3)
Peripheral artery disease — no. (%) 83 (10.0) 82 (10.0)
Previous venous thromboembolism — no. (%) 18 (2.2) 15 (1.8)
Permanent pacemaker — no. (%) 80 (9.7) 80 (9.8)
Chronic obstructive pulmonary disease — no. (%) 110 (13.3) 88 (10.8)
Glomerular filtration rate — ml/min/1.73 m2 73.4±23.8 73.2±23.2
Procedural characteristics
Valve type — no. (%)
Sapien XT, Edwards Lifesciences 13 (1.6) 13 (1.6)
Sapien 3, Edwards Lifesciences 385 (46.6) 346 (42.3)
CoreValve, Medtronic 33 (4.0) 35 (4.3)
CoreValve Evolut R, Medtronic 206 (24.9) 225 (27.5)
Lotus, Boston Scientific 44 (5.3) 40 (4.9)
Portico, St. Jude Medical 44 (5.3) 40 (4.9)
Acurate Neo, Boston Scientific 82 (9.9) 89 (10.9)
Other 19 (2.3) 30 (3.7)
Valve-in-valve — no. (%) 42 (5.1) 49 (6.0)
Table 1. Baseline Characteristics of the Patients.*
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Characteristic
Rivaroxaban Group 
(N = 826)
Antiplatelet Group 
(N = 818)
Post-TAVR echocardiographic characteristics
Aortic valve area — cm2 1.8±0.6 1.9±0.5
Mean aortic valve gradient — mm Hg 10.0±4.7 10.1±4.6
Left ventricular ejection fraction — % 57.4±10.9 58.2±11.2
Paravalvular aortic regurgitation — no. (%)
Mild 157 (19.0) 168 (20.5)
Moderate or severe 10 (1.2) 10 (1.2)
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. NYHA denotes New York Heart 
Association, and TAVR transcatheter aortic-valve replacement.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡  Scores on the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II), which measure patient risk  
at the time of cardiovascular surgery, are calculated by means of logistic-regression equations. A score of greater than 
10% indicates high risk, 5 to 10% intermediate risk, and less than 5% low risk.
§  Society of Thoracic Surgeons (STS) risk scores, which measure patient risk at the time of cardiovascular surgery, are 
calculated by means of logistic-regression equations. A score of greater than 8% indicates high risk, 3 to 8% intermedi-
ate risk, and less than 3% low risk.
¶  Coronary artery disease was defined as previous myocardial infarction, percutaneous coronary intervention, or coronary-
artery bypass grafting.
Table 1. (Continued.)
Figure 1. Screening, Randomization, and Follow-up.
1644 Underwent randomization
1674 Patients were assessed for eligibility
30 Provided consent but did not
undergo randomization
1 Had adverse event
17 Had screening failure
6 Withdrew
6 Had other reason
826 Were assigned to the rivaroxaban group
801 (97.0%) Received rivaroxaban
25 (3.0%) Did not receive rivaroxaban
818 Were assigned to the antiplatelet group
807 (98.7%) Received antiplatelet drug
11 (1.3%) Did not receive antiplatelet drug
26 (3.2%) Did not complete trial
21 (2.6%) Withdrew consent
5 (0.6%) Were lost to follow-up
27 (3.3%) Did not complete trial
1 (0.1%) Had adverse event
21 (2.5%) Withdrew consent
5 (0.6%) Were lost to follow-up
799 (96.7%) Completed trial 792 (96.8%) Completed trial
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ratio, 1.23; 95% CI, 0.71 to 2.15) (Tables S10 and 
S11 and Figs. S7 through S9). Kaplan–Meier curves 
for death from any cause after premature perma-
nent trial drug discontinuation are provided in 
Figure S10.
Discussion
GALILEO was a randomized, controlled trial to 
evaluate the efficacy and safety of rivaroxaban-
based antithrombotic therapy as compared with 
antiplatelet-based therapy after successful TAVR 
in patients without an established indication for 
anticoagulation. A dose of rivaroxaban of 10 mg 
daily (lower than the approved dose for stroke 
prevention in patients with atrial fibrillation) 
was selected to provide a level of anticoagulation 
to prevent valve surface thromboembolism while 
mitigating bleeding complications.
We observed that the rivaroxaban group had 
higher rates of death or thromboembolic com-
plications in the intention-to-treat analysis (rates 
that were attenuated in the on-treatment analy-
sis) and higher rates of bleeding complications. 
These results underscore the challenge of anti-
thrombotic therapy in the TAVR population, which 
includes patients who are generally elderly, po-
tentially frail, or affected by multiple coexisting 
conditions associated with an increased risk of 
both bleeding and thromboembolic events. The 
lack of a clinical benefit of rivaroxaban in this 
context occurred despite evidence from an imag-
ing substudy of GALILEO (also now published in 
the Journal)21 that rivaroxaban was associated with 
a lower incidence of subclinical valve-leaflet thick-
ening and reduced leaflet motion than antiplate-
let therapy.
Figure 2. Cumulative Risk of the Primary Efficacy  
and Primary Safety Outcomes and Death from Any 
Cause (Intention-to-Treat Analysis).
Shown are time-to-event Kaplan–Meier curves for the 
primary efficacy outcome, death from any cause, and 
the primary safety outcome. The primary efficacy out-
come was defined as the composite of death, stroke, 
myocardial infarction, symptomatic valve thrombosis, 
pulmonary embolism, deep-vein thrombosis, or sys-
temic embolism. The primary safety outcome was de-
fined as the composite of Valve Academic Research 
Consortium life-threatening, disabling, or major bleed-
ing. The 95% confidence intervals (CIs) presented 
were not adjusted for multiple comparisons. Insets 
show the same data on an enlarged y axis.
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The overall event rates in this trial were lower 
than anticipated, probably reflecting the prereq-
uisite of a successfully completed procedure and 
the overall declining risk profile among patients 
referred for TAVR (because of expanding indica-
tions). However, the rates are in line with those 
in the pivotal trials involving low-risk and inter-
mediate-risk populations.6,7 Although the rou-
tine use of higher-dose rivaroxaban (15 to 20 mg 
daily) in this trial population would have been 
expected to increase bleeding complications, we 
do not know whether a lower dose (e.g., 2.5 mg 
twice daily) might have afforded an improved 
risk–benefit profile as compared with the pres-
ent results.
The higher number of deaths in the rivaroxa-
ban group than in the antiplatelet group did not 
appear to be directly attributable to the higher 
Outcome
Rivaroxaban Group 
(N = 826)
Antiplatelet Group 
(N = 818)
Difference 
(95% CI)
Hazard Ratio 
(95% CI)
no. (%)
incidence rate/ 
100 person-yr no. (%)
incidence rate/ 
100 person-yr
incidence rate/ 
100 person-yr
Efficacy outcomes
Primary efficacy outcome† 105 (12.7) 9.8 78 (9.5) 7.2 2.6 (0.1 to 5.1) 1.35 (1.01 to 1.81)
Death 64 (7.7) 5.8 38 (4.6) 3.4 2.4 (0.6 to 4.1) 1.69 (1.13 to 2.53)
From cardiovascular causes 35 (4.2) 3.2 27 (3.3) 2.4 0.7 (−0.7 to 2.1) 1.30 (0.79 to 2.14)
From noncardiovascular causes 29 (3.5) 2.6 11 (1.3) 1.0 1.6 (0.5 to 2.7) 2.67 (1.33 to 5.35)
Stroke 30 (3.6) 2.8 25 (3.1) 2.3 0.5 (−0.8 to 1.8) 1.20 (0.71 to 2.05)
Ischemic 28 (3.4) 2.6 22 (2.7) 2.0 0.6 (−0.7 to 1.8) 1.28 (0.73 to 2.23)
Hemorrhagic 2 (0.2) 0.2 3 (0.4) 0.3 −0.1 (−0.5 to 0.3) 0.67 (0.11 to 3.98)
Myocardial infarction 23 (2.8) 2.1 17 (2.1) 1.5 0.6 (−0.6 to 1.7) 1.37 (0.73 to 2.56)
Symptomatic valve thrombosis 3 (0.4) 0.3 7 (0.9) 0.6 −0.4 (−0.9 to 0.2) 0.43 (0.11 to 1.66)
Pulmonary embolism 3 (0.4) 0.3 2 (0.2) 0.2 0.1 (−0.3 to 0.5) 1.49 (0.25 to 8.93)
Deep-vein thrombosis 1 (0.1) 0.1 4 (0.5) 0.4 −0.3 (−0.7 to 0.1) 0.25 (0.03 to 2.23)
Systemic embolism 1 (0.1) 0.1 1 (0.1) 0.1 0.0 (−0.3 to 0.3) 0.98 (0.06 to 15.69)
Key secondary efficacy outcome‡ 83 (10.0) 7.8 68 (8.3) 6.3 1.5 (−0.8 to 3.7) 1.22 (0.89 to 1.69)
Net clinical benefit§ 137 (16.6) 13.2 100 (12.2) 9.4 3.8 (0.9 to 6.7) 1.39 (1.08 to 1.80)
Safety outcomes
Primary safety outcome¶ 46 (5.6) 4.3 31 (3.8) 2.8 1.5 (−0.1 to 3.1) 1.50 (0.95 to 2.37)
VARC life-threatening or disabling 
bleeding
18 (2.2) 1.6 17 (2.1) 1.5 0.1 (−1.0 to 1.2) 1.06 (0.55 to 2.06)
Fatal bleeding 2 (0.2) 0.2 1 (0.1) 0.1 0.1 (−0.2 to 0.4) 2.01 (0.18 to 22.19)
VARC major bleeding 30 (3.6) 2.8 15 (1.8) 1.4 1.4 (0.2 to 2.6) 2.02 (1.09 to 3.76)
TIMI major or minor bleeding 42 (5.1) 3.9 24 (2.9) 2.2 1.7 (0.3 to 3.2) 1.78 (1.08 to 2.94)
ISTH major bleeding 49 (5.9) 4.6 30 (3.7) 2.7 1.9 (0.2 to 3.5) 1.66 (1.05 to 2.62)
BARC type 2, 3, or 5 bleeding 148 (17.9) 15.4 85 (10.4) 8.2 7.2 (4.2 to 10.3) 1.84 (1.41 to 2.41)
*  The 95% confidence intervals (CIs) were not adjusted for multiple comparisons. The proportionality assumption for the primary efficacy and 
safety outcomes was not violated. BARC denotes Bleeding Academic Research Consortium, ISTH International Society on Thrombosis and 
Hemostasis, TIMI Thrombolysis in Myocardial Infarction, and VARC Valve Academic Research Consortium.
†  The primary efficacy outcome was defined as the composite of death, stroke, myocardial infarction, symptomatic valve thrombosis, pulmo-
nary embolism, deep-vein thrombosis, or systemic embolism.
‡  The key secondary efficacy outcome was defined as the composite of death from cardiovascular causes, stroke, myocardial infarction, symp-
tomatic valve thrombosis, pulmonary embolism, deep-vein thrombosis, or systemic embolism.
§  Net clinical benefit was defined as the composite of the primary efficacy and primary safety outcomes.
¶  The primary safety outcome was defined as the composite of VARC life-threatening, disabling, or major bleeding.
Table 2. Efficacy and Safety Outcomes (Intention-to-Treat Analysis).*
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risk of bleeding in the rivaroxaban group. Among 
patients assigned to rivaroxaban who died, only 
a minority had a major bleeding event, myocar-
dial infarction, or stroke within 30 days before 
death, and most deaths occurred long after dis-
continuation of the trial drug. Most of the adju-
dicated causes of death in the rivaroxaban group 
were sudden or from unknown reasons, as well 
as due to noncardiovascular causes. Hence, the 
mechanism underlying the higher mortality in 
the rivaroxaban group observed in the intention-
to-treat analysis in this trial is unclear. The be-
tween-group differences in mortality were attenu-
ated in the on-treatment analysis.
Since the inception of TAVR, postprocedural 
antithrombotic therapy has been based on expert 
consensus according to regimens used in the 
pivotal trials.14,15,22-24 Recent registry results have 
indicated an association between oral anticoag-
ulation at hospital discharge and an increased 
risk of death but a decreased risk of bioprosthetic 
valve dysfunction in comparison to patients un-
dergoing TAVR who did not receive anticoagula-
tion therapy.25 Whether a short-term course of 
anticoagulation monotherapy after TAVR is safe 
and effective warrants further investigation. The 
90-day landmark analyses that we conducted 
did not suggest consistent differential effects 
over time.
GALILEO was an open-label trial and was po-
tentially subject to reporting and ascertainment 
bias. However, trial outcomes were prespecified 
with the use of standardized definitions and ad-
judicated by a clinical-events committee whose 
members were unaware of the trial-group as-
signments. Patients undergoing TAVR with an 
established indication for anticoagulation were 
not included in this trial, and treatment strategies 
for this patient population are being investigated 
in ongoing studies (ClinicalTrials.gov numbers, 
NCT02247128, NCT02664649, NCT02943785, and 
NCT02735902). On-treatment analyses are gen-
erally subject to misinterpretation since they 
effectively subvert the randomization, because pa-
tients who continue to receive treatment differ 
from those who do not, and thus their subse-
quent risk of an event is no longer comparable 
between the trial groups. In the present trial, 
in which there was a substantial imbalance in 
treatment discontinuation, the on-treatment 
analysis may be biased as described above. The 
P values in this article must be read with pru-
dence, because these tests were not prespecified. 
Because we report multiple confidence inter-
vals in the context of a trial that was prema-
turely terminated, all estimated treatment ef-
fects and their confidence intervals should be 
interpreted with caution. Finally, the early trial 
termination constitutes a limitation in its own 
right.
Among patients without an established indi-
cation for anticoagulation after successful TAVR, 
a treatment strategy including anticoagulation 
with rivaroxaban at a dose of 10 mg daily was 
associated with a higher risk of death or throm-
boembolic complications and a higher risk of 
bleeding than an antiplatelet-based strategy.
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